Acute Heart Failure
Conditions
Keywords
Acute heart failure, Metabolic modulation
Brief summary
The primary objective of this study is to evaluate whether metabolic modulation improves hemodynamics and outcome in acute heart failure
Detailed description
Acute heart failure is a serious disease that despite modern therapies carries a high mortality. Inotropic drugs improve patient status but yield a higher risk of death. Previous studies have shown that myocardial contractility improves when glucose fermentation is up regulated and decreases when Free Fatty Acids are high. In a placebo-controlled design we wish to shift myocardial substrate metabolism towards increased glucose uptake and utilization and measure hemodynamics and biochemical markers of metabolism and prognosis.
Interventions
DRUGacipimox
Sponsors
University of Aarhus
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Acute heart failure * NYHA class III - IV. * ejection fraction \<35
Exclusion criteria
* Age \<18 år or \>85 år, * allergy * renal failure * recently developed brady- or tachy-arrythmias * Serious infection * Heart failure due to restrictive or hypertrophic cardiomyopathy or stenotic valvular heart disease * Recent Myocardial infarction (\<6 Weeks) * Pulmonary Wedge pressure \>30 mm Hg * diabetes mellitus treated with insulin * peptic ulcer * pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac index | — |
| pulmonary Wedge Pressure | — |
| Ejection fraction | — |
Secondary
| Measure | Time frame |
|---|---|
| myocardial glucose- and Free Fatty Acid-extraction | — |
| outcome day 6 and 30 | — |
| cardiac output | — |
| Regional left ventricle function | — |
Countries
Denmark
Outcome results
None listed